Cognitive-Functional Intervention for Adults With ADHD (Cog-Fun-A): An Extreme Case Series Analysis.

OTJR (Thorofare N J)Jul 8, 2026 (epub)
Case ReportPsychiatryPhysical Medicine & RehabilitationOpen access

Ifat Velder Shukrun, Jennifer R Budman, Adina Maeir

✦ AI-curated · Sources linked

Case in brief

This report presents three adults with ADHD who participated in the Cognitive-Functional Intervention for Adults (Cog-Fun-A) program. Two participants exhibited significant improvements in occupational performance, satisfaction, quality of life, and self-regulation, while one participant showed minimal change due to inconsistent attendance and difficulty applying learned strategies. The findings highlight variability in engagement and outcomes among individuals with ADHD.

Diagnostic / clinical pearl

Clinicians should consider individual factors such as motivation, routine stability, and environmental support when evaluating the potential effectiveness of occupational therapy interventions for adults with ADHD.

Why it matters

Understanding the variability in response to occupational therapy can inform tailored approaches for adults with ADHD, enhancing the effectiveness of interventions like Cog-Fun-A.

Source

PubMed · PMID 42421291Free full text on PubMed Central

Published in OTJR (Thorofare N J). This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Psychiatry

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.